

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal (STA)

Sofosbuvir in combination with velpatasvir for treating chronic hepatitis C [ID921]

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Gilead Sciences (sofosbuvir and velpatasvir) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Addaction • Addiction Today (Addiction Recovery Foundation) • ADFAM • African Health Policy Network • Black Health Agency • British Liver Trust • Compass UK • GMFA - The Gay Men's Health Charity • Hepatitis C Trust • HIV i Base • Lifeline Project • Liver4Life • Muslim Council of Britain • NAM Publications • National AIDS Trust • Positively UK • South Asian Health Foundation • Specialised Healthcare Alliance • Terrence Higgins Trust • UK Harm Reduction Alliance • UK Thalassaemia Society • YouthNet <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association for Clinical Biochemistry and Laboratory Medicine • British Association for Sexual Health and HIV 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Drugs Action • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Blood and Transplant • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Abbvie (ombitasvir, paritaprevir, ritonavir, and dasabuvir) • Bristol-Myers Squibb (daclatasvir) • Gilead Sciences (sofosbuvir, ledipasvir/sofosbuvir Janssen (simeprevir, telaprevir) • Meda Pharmaceuticals (ribavirin) • Merck Sharp & Dohme (boceprevir, peginterferon alfa 2b, ribavirin) • Mylan UK (ribavirin) • Roche Products (peginterferon alfa 2a, ribavirin) • Teva UK (ribavirin)

National Institute for Health and Care Excellence
 Provisional matrix for the proposed technology appraisal of sofosbuvir in combination with velpatasvir for treating chronic hepatitis C [ID921]

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Association for the Study of the Liver • British Association for the Study of the Liver Nurses Forum • British Geriatrics Society • British HIV Association • British Infection Association • British Liver Nurses Forum • British Society of Gastroenterology • British Transplantation Society • British Viral Hepatitis Group • HCV Action • Hepatitis Nurse Specialist Forum • Infection Control Nurses Association • Medical Foundation for AIDS & Sexual Health • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for General Microbiology • UK Clinical Pharmacy Association • UK Clinical Virology Network <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS Southend CCG • NHS Tameside and Glossop CCG • Welsh Government 	<p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Hepato-Biliary Group • Foundation for Liver Research • MRC Clinical Trials Unit • National Institute of Health Research • UCL Centre for Sexual Health & HIV Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: of the companies that markets comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.